We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+15.27%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$17.3B
AUM Growth
+$1.38B
Cap. Flow
-$440M
Cap. Flow %
-2.54%
Top 10 Hldgs %
32.07%
Holding
728
New
61
Increased
216
Reduced
343
Closed
55

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$85M
2
ABT icon
Abbott
ABT
+$53.8M
3
EXC icon
Exelon
EXC
+$46.6M
4
BSX icon
Boston Scientific
BSX
+$42.6M
5
ABBV icon
AbbVie
ABBV
+$32.4M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$80.5M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$54.5M
3
CRWD icon
CrowdStrike
CRWD
+$45.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$40.6M
5
MRK icon
Merck
MRK
+$39.3M

Sector Composition

Rank Sector Weight
1 Technology 36.26%
2 Healthcare 22.78%
3 Financials 10.33%
4 Consumer Discretionary 7.75%
5 Industrials 7.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SOLV icon
376
Solventum
SOLV
$14.8B
$4.13M 0.02%
+54,494
New +$3.86M
BR icon
377
Broadridge
BR
$18.6B
$4.13M 0.02%
17,004
+1,457
+9% +$346K
CCI icon
378
Crown Castle
CCI
$34.1B
$4.04M 0.02%
39,369
+1,795
+5% +$182K
FTV icon
379
Fortive
FTV
$19.6B
$4.04M 0.02%
77,442
-24,672
-24% -$1.29M
BDX icon
380
Becton Dickinson
BDX
$45.5B
$3.98M 0.02%
23,077
-3,878
-14% -$711K
OKE icon
381
Oneok
OKE
$55.8B
$3.96M 0.02%
48,557
-6,937
-13% -$578K
ULS icon
382
UL Solutions
ULS
$18.4B
$3.95M 0.02%
54,223
-894
-2% -$58.5K
ALAB icon
383
Astera Labs
ALAB
$44.2B
$3.94M 0.02%
+43,598
New +$3.44M
RBLX icon
384
Roblox
RBLX
$35.9B
$3.93M 0.02%
37,402
+3,991
+12% +$314K
DXCM icon
385
DexCom
DXCM
$29B
$3.88M 0.02%
44,455
-1,141
-3% -$89.4K
LNN icon
386
Lindsay Corp
LNN
$1.18B
$3.85M 0.02%
26,656
-8,518
-24% -$1.14M
EA icon
387
Electronic Arts
EA
$52.5B
$3.77M 0.02%
23,634
-34,269
-59% -$5.07M
TSCO icon
388
Tractor Supply
TSCO
$16.8B
$3.75M 0.02%
70,986
-42,962
-38% -$2.2M
RY icon
389
Royal Bank of Canada
RY
$293B
$3.73M 0.02%
28,348
-19,483
-41% -$2.38M
SYRE icon
390
Spyre Therapeutics
SYRE
$8.29B
$3.68M 0.02%
246,030
RSG icon
391
Republic Services
RSG
$67.6B
$3.65M 0.02%
14,808
+2,046
+16% +$506K
PRCT icon
392
Procept Biorobotics
PRCT
$1.02B
$3.64M 0.02%
63,125
+32,301
+105% +$1.83M
TNGX icon
393
Tango Therapeutics
TNGX
$4.23B
$3.63M 0.02%
+708,812
New +$1.75M
AIG icon
394
American International
AIG
$42.6B
$3.63M 0.02%
42,363
-8,008
-16% -$667K
MPC icon
395
Marathon Petroleum
MPC
$89.9B
$3.62M 0.02%
21,818
-3,269
-13% -$490K
OLMA icon
396
Olema Pharmaceuticals
OLMA
$983M
$3.62M 0.02%
850,454
-63
-0% -$281
CMI icon
397
Cummins
CMI
$87.3B
$3.58M 0.02%
10,932
-5,364
-33% -$1.66M
CELC icon
398
Celcuity
CELC
$4B
$3.52M 0.02%
263,576
-14
-0% -$152
VMC icon
399
Vulcan Materials
VMC
$37.2B
$3.45M 0.02%
9,608
+1,644
+21% +$423K
ITT icon
400
ITT
ITT
$17.7B
$3.44M 0.02%
21,935
-1,436
-6% -$205K

Similar funds

Candriam SCA's Q2 2025 Portfolio in Review

As of Q2 2025, Candriam SCA held 728 positions worth $17.3B, up 8.6% from $16B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Candriam SCA's Q2 2025 filing shows 61 new, 216 increased, 343 reduced and 55 closed positions. Its largest new stake was Tapestry: 260,834 shares worth $22.9M. The largest sale was Tesla, an estimated $80.5M.

By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q2 2025 buy was Tapestry: 260,834 shares worth $22.9M.
  • Candriam SCA added most to Broadcom in Q2 2025, an estimated $85M increase.
  • Candriam SCA's biggest Q2 2025 reduction was Tesla, cutting an estimated $80.5M.
  • Candriam SCA fully exited Banco Macro in Q2 2025, selling an estimated $17.6M.
  • Candriam SCA's ten largest holdings make up 32% of its $17.3B portfolio in Q2 2025.
  • Candriam SCA opened 61 new positions and closed 55 in Q2 2025.
  • Candriam SCA's portfolio value rose 8.6% quarter-over-quarter to $17.3B.

Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.